Methods and compositions for treating post-operative pain comprising clonidine
The present invention is directed to an implantable drug depot useful for reducing, preventing or treating post-operative pain in a patient in need of such treatment, the implantable drug depot comprising a therapeutically effective amount of clonidine or pharmaceutically acceptable salt thereof and a polymer; wherein the depot is implantable at a site beneath the skin to reduce, prevent or treat post-operative pain, and the depot is capable of releasing (i) about 5% to about 45% of the clonidine or pharmaceutically acceptable salt thereof relative to a total amount of the clonidine or pharmaceutically acceptable salt thereof loaded in the drug depot over a first period of up to 48 hours and (ii) about 55% to about 95% of the clonidine or pharmaceutically acceptable salt thereof relative to a total amount of the clonidine or pharmaceutically acceptable salt thereof loaded in the drug depot over a subsequent period of at least 3 days.
1. An implantable drug depot useful for reducing or treating post-operative pain in a patient in need of such treatment, the implantable drug depot comprising a therapeutically effective amount of clonidine or pharmaceutically acceptable salt thereof and a polymer comprising poly(D,L-lactide-co-caprolactone) or poly(L-lactide-co-caprolactone) or a combination thereof; wherein the depot is implantable at a site beneath the skin to reduce or treat post-operative pain, and the depot is capable of releasing (i) about 5% to about 45% of the clonidine or pharmaceutically acceptable salt thereof relative to a total amount of the clonidine or pharmaceutically acceptable salt thereof loaded in the drug depot over a first period of up to 48 hours and (ii) about 55% to about 95% of the clonidine or pharmaceutically acceptable salt thereof relative to a total amount of the clonidine or pharmaceutically acceptable salt thereof loaded in the drug depot over a subsequent period of at least 3 days, and the polymer comprises an inherent viscosity from about 0.10 dL/g to about 1.2 dL/g.
2. An implantable drug depot according to claim 1 , wherein the clonidine is in the form of a hydrochloric salt.
3. An implantable drug depot according to claim 1 , wherein the polymer comprises one or more of poly(lactide-co-glycolide), polylactide, polyglycolide, polyorthoester, D-lactide, D,L-lactide, poly(D,L-lactide), L-lactide, poly(D,L-lactide-co-glycolide-co-caprolactone), polycaprolactone or a combination thereof.
4. An implantable drug depot according to claim 1 , wherein the polymer comprises about 60% to about 90% of the total wt. % of the drug depot.
5. An implantable drug depot according to claim 1 , wherein the polymer is capable of degrading in 30 days or less after the drug depot is implanted at the site.
6. An implantable drug depot according to claim 1 , wherein the clonidine is released in an amount between 0.05 ug and 3 mg per day for a period of 3 to 10 days.
7. An implantable drug depot according to claim 1 , wherein the clonidine is present in an amount of about 0.1 to about 10 wt. % of the implantable drug depot and the polymer is present in an amount of about 75 to about 94 wt. % of the implantable drug depot, and the drug depot further comprises from about 5 to about 15 wt. % of an excipient.
8. An implantable drug depot according to claim 1 , wherein the clonidine is present in an amount of about 0.1 to about 10 wt. % of the implantable drug depot and the polymer comprises PLGA in an amount of about 75 to about 94 wt. % of the depot, and the depot further comprises from about 5 to about 15 wt. % mPEG.
9. A method of making an implantable drug depot of claim 1 , the method comprising combining a biocompatible polymer and a therapeutically effective amount of the clonidine or pharmaceutically acceptable salt thereof and forming the implantable drug depot from the combination.
10. A method of treating post-operative pain in a patient in need of such treatment, the method comprising delivering one or more biodegradable drug depots comprising a polymer; and a therapeutically effective amount of clonidine or pharmaceutically acceptable salt thereof to a target tissue site beneath the skin before, during or after surgery, wherein the drug depot is capable of releasing an initial bolus dose of the clonidine or pharmaceutically acceptable salt thereof at a site beneath the skin followed by a sustained release dose of an effective amount of the clonidine or pharmaceutically acceptable salt thereof over a period of at least 3 days, and the polymer comprises an inherent viscosity from about 0.45 dL/g to about 1.0 dL/g.
11. A method of treating post-operative pain according to claim 10 , wherein the drug depot releases about 55% to about 85% of the clonidine or pharmaceutically acceptable salt thereof relative to a total amount of the clonidine loaded in the drug depot over a period of 3 to 10 days after the drug depot is administered to the target tissue site.
12. A method of treating post-operative pain according to claim 10 , wherein the drug depot releases between 0.05 ug and 3 mg/day of the clonidine or pharmaceutically acceptable salt thereof for a period of 4 to 10 days.
13. A method of treating post-operative pain according to claim 10 , wherein the polymer comprises one or more of poly(lactide-co-glycolide), polylactide, polyglycolide, polyorthoester, D-lactide, D,L-lactide, poly(D,L-lactide), L-lactide, poly(D,L-lactide-co-caprolactone), poly(D,L-lactide-co-glycolide-co-caprolactone), polycaprolactone or a combination thereof.
14. A method of treating post-operative pain according to claim 10 , wherein the polymer comprises about 60% to about 90% of the total wt. % of the drug depot.
15. An implantable drug depot comprising: (i) a therapeutically effective amount of clonidine or pharmaceutically acceptable salt thereof; and (ii) a polymer;
wherein the drug depot is capable of releasing an initial bolus dose of clonidine or pharmaceutically acceptable salt thereof at a site beneath the skin, and the drug depot is capable of releasing a sustained release dose of an effective amount of clonidine or pharmaceutically acceptable salt thereof over a subsequent period of 3 to 10 days; and
wherein the polymer comprises poly(D,L-lactide-co-caprolactone) or poly(L-lactide-co- caprolactone) or a combination thereof, and the polymer comprises an inherent viscosity from about 0.45 dL/g to about 1.0 dL/g.
16. An implantable drug depot according to claim 15 , wherein the drug depot releases about 55% to about 85% of the clonidine or pharmaceutically acceptable salt thereof relative to a total amount of clonidine loaded in the drug depot over the subsequent period of 3 to 10 days after the drug depot is administered.
17. An implantable drug depot according to claim 15 wherein the drug depot releases between 0.05 ug and 3 mg/day of clonidine or pharmaceutically acceptable salt thereof.
18. An implantable drug depot according to claim 15 , wherein the polymer comprises about 60% to about 90% of the total wt. % of the drug depot.
19. An implantable drug depot according to claim 15 , wherein the clonidine is in the form of a hydrochloric salt.
20. An implantable drug depot according to claim 15 , wherein the initial bolus dose of the clonidine is about 15% to about 45% of the clonidine or pharmaceutically acceptable salt thereof relative to a total amount of clonidine loaded in the drug depot.
21. An implantable drug depot according to claim 1 , wherein the depot is in the form of a strip.